Androgenetic alopecia: pathogenesis and potential for therapy
JA Ellis, R Sinclair, SB Harrap - Expert reviews in molecular …, 2002 - cambridge.org
… Tel: +61 3 8344 5836; Fax: +61 3 9349 4519; E-mail: s.harrap@unimelb.edu.au … The
exact mechanism(s) through which androgens act to cause baldness remain unclear; however, …
exact mechanism(s) through which androgens act to cause baldness remain unclear; however, …
Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society …
…, RM Touyz, D Sica, SB Harrap - Journal of …, 2014 - journals.lww.com
… s ASH Comprehensive Hypertension Center, University of Chicago Medicine, Chicago,
Illinois, USA … Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies …
Illinois, USA … Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies …
The ACE2 gene: its potential as a functional candidate for cardiovascular disease
LM Burrell, SB Harrap, E Velkoska, SK Patel - Clinical science, 2013 - portlandpress.com
The RAS (renin–angiotensin system) plays an important role in the pathophysiology of CVD
(cardiovascular disease), and RAS blockade is an important therapeutic strategy in the …
(cardiovascular disease), and RAS blockade is an important therapeutic strategy in the …
[HTML][HTML] Follow-up of blood-pressure lowering and glucose control in type 2 diabetes
Background In the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified
Release Controlled Evaluation (ADVANCE) factorial trial, the combination of perindopril …
Release Controlled Evaluation (ADVANCE) factorial trial, the combination of perindopril …
[HTML][HTML] Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes
… Approval for the trial was obtained from each centre’s institutional review board and all …
events was also estimated using Fine and Gray’s test where all-cause death was considered as a …
events was also estimated using Fine and Gray’s test where all-cause death was considered as a …
The genetics of androgenetic alopecia
JA Ellis, SB Harrap - Clinics in dermatology, 2001 - cidjournal.com
… In Kuster and Happle’s analysis of the inheritance of androgenetic alopecia, several arguments
were put forward to support a polygenic mode of inheritance. These included the fact that …
were put forward to support a polygenic mode of inheritance. These included the fact that …
[HTML][HTML] Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds
…, S Harrap, P Hamet, S Heller, S MacMahon… - Diabetologia, 2012 - Springer
Aims/hypothesis There is conflicting evidence regarding appropriate glycaemic targets for
patients with type 2 diabetes. Here, we investigate the relationship between HbA 1c and the …
patients with type 2 diabetes. Here, we investigate the relationship between HbA 1c and the …
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
The prevalence of diabetes is increasing worldwide, and most people with diabetes will die
or be disabled as a consequence of vascular complications.1,2 Prospective studies have …
or be disabled as a consequence of vascular complications.1,2 Prospective studies have …
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial
OBJECTIVE There is no consensus on the importance of visit-to-visit glycemic variability in
diabetes. Therefore, we assessed the effects of visit-to-visit variability (VVV) in HbA 1c and …
diabetes. Therefore, we assessed the effects of visit-to-visit variability (VVV) in HbA 1c and …
Lowering blood pressure reduces renal events in type 2 diabetes
BP is an important determinant of kidney disease among patients with diabetes. The
recommended thresholds to initiate treatment to lower BP are 130/80 and 125/75 mmHg for people …
recommended thresholds to initiate treatment to lower BP are 130/80 and 125/75 mmHg for people …